Europe Cyclic Olefin Polymer Cop Injectable Vials Market Size & Outlook, 2026-2034
Europe Cyclic Olefin Polymer Cop Injectable Vials Market Insights
- Based on Packaging Market Insights findings, the Europe Cyclic Olefin Polymer Cop Injectable Vials Market size reached USD 0.39 Million in 2025 and is expected to grow to USD 0.96 Million by 2034.
- During 2026–2034, the market is forecasted to advance at a CAGR of 10.51%.
- Sterile COP Injectable Vials represented the largest share of the By Type market in terms of size in 2025.
- Among the By Type segments, Sterile COP Injectable Vials is forecasted to achieve the highest growth and remain the most lucrative through the forecast period.
Source: PIAnalysis Company Publications, Primary Interviews.
Other Key Findings
- Europe held 39% share of the global Cyclic Olefin Polymer Cop Injectable Vials Market size in 2025.
- United States is expected to remain the largest contributor to the global market size by 2034.
- By 2034, United Kingdom is anticipated to record the highest growth in Europe, with the market size expected to reach USD 0.2 Million.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 0.39 Million |
| Market Size In 2034 | USD 0.96 Million |
| Largest segment | Sterile COP Injectable Vials |
| Units | Revenue in USD Million |
| CAGR | 10.51% (2026-2034) |
| Segmnetation Covered | |
| Europe |
|
| By Type |
|
| By Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Europe Cyclic Olefin Polymer Cop Injectable Vials Market Country 2026-2034 (USD Million)
| Europe | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Germany | XX.x | XX.x | XX.x | 0.1 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| United Kingdom | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| France | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Italy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Spain | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Russia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nordic | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Benelux | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Europe Cyclic Olefin Polymer Cop Injectable Vials Market By Type 2026-2034 (USD Million)
| By Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sterile COP Injectable Vials | XX.x | XX.x | XX.x | 0.18 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ready-to-Fill COP Injectable Vials | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| High-Barrier COP Injectable Vials | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Europe Cyclic Olefin Polymer Cop Injectable Vials Market By Application 2026-2034 (USD Million)
| By Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biologics | XX.x | XX.x | XX.x | 0.2 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vaccines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Injectable Pharmaceuticals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.